STAT+: Invivyd’s pursuit of a Covid vaccine alternative gets a lift, but an FDA hurdle may await — SkimNews
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- Invivyd on Tuesday reported Phase 3 LIBERTY study results showing its injectable, low-dose monoclonal antibody candidate VYD2311 was statistically significantly better tolerated than Pfizer's mRNA vaccine Comirnaty.
- Six days after dosing, 57% of VYD2311 participants experienced headaches, chills, fatigue, or injection-site pain — the typical vaccination reactions — versus 91% in the Comirnaty arm.
- VYD2311 sustained its tolerability edge over Comirnaty at the 56-day mark and was shown to be safe when co-administered with Comirnaty.
- Invivyd is positioning VYD2311 as a Covid vaccine alternative that avoids the real or perceived limitations of vaccines, including side-effect burden and mRNA-related concerns.
- The headline flags a likely FDA regulatory hurdle ahead for VYD2311, though details of that barrier sit behind the STAT+ paywall in the original piece.
- The company is a small biotech; Phase 3 readout is its first major late-stage data update since the author last profiled it in August 2025.
Why it matters: VYD2311 cut the six-day side-effect rate from 91% to 57% versus the dominant mRNA vaccine — a clinically large tolerability gap that, if it survives the FDA, gives Covid-vaccine-hesitant patients an injectable monoclonal alternative backed by head-to-head Phase 3 data rather than a placebo comparison.
Ask SkimNews
